Roche And Chiasma Announce Collaboration To Develop And Commercialize Chiasma's Octreolin® For Acromegaly And Neuroendocrine Tumors
About Chiasma Chiasma is developing oral drugs that previously were only available by injection, thereby providing patients with pain-free medications that are self-administered. The Company's lead candidate is an oral form of the peptide octreotide, initially being developed for patients with acromegaly that is in a Phase 3 (pivotal) trial. Chiasma is evaluating additional proteins, peptides and small molecules that can be applied to its proprietary Transient Permeability Enhancer (TPE) technology to enable oral delivery of drugs that previously were available by injection only. Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. Additional information can be found at www.ChiasmaPharma.com.
About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Forward-Looking Statements This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the Transient permeability Enhancer (TPE) system. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.SOURCE Chiasma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts